Conversely, administration of CD25-blocking monoclonal antibody daclizumab led to significant and prolonged decrease in peripheral CD25+FOXP3+CD4 T cells in patients with metastatic breast cancer in the absence of autoimmunity [44]. Here, CD4 is linked to Autoimmunity.